Wednesday, August 26, 2020 12:39:35 PM
My take: the ultimate buying opportunity is happening right in front of our eyes!
It spiked to almost 30, so profit taking was in the cards.
The $22.5 private placement could have risen the indication that the stock spiked too fast. (But a discount within a PP is normal, due to trading restrictions on the certificates.)
EBITDA forecast Q3 is lower than the realised Q2 EBITDA. But that makes complete sense because:
-hiring of reps has been going on at an increased pace. Thanks to COVID more salesmen were 'for hire'. 335 reps hired at July 28 (day of CC). If they will be able to hire 40 additional reps / month (like they did in the last months), the ultimate goal of 500 reps will be reached in November 2020. Remember that they indicated to go for 400 sales reps by the end of 2020 in a previous CC!
-these salesmen, when starting their jobs, initially cost more money than they 'deliver'. Think of training costs, while skills have to be developed along the way.
These reps will not be sitting idle. As Sandgaard stated, an experienced sales rep is able to generate revenues of $1 million / year!
Gross margins remain stable. (80+ %)
Hiring pace will decrease at the end of the year and revenues per rep will increase sharply during the end of 2020, but certainly in 2021.
So you do the math…
I stand with my $100.- shareprice in 2021, ultimately 2022.
GLTA. I am loaded with ZYXI
Recent ZYXI News
- Zynex Reports First Quarter 2024 Financial Results • PR Newswire (US) • 04/30/2024 08:01:00 PM
- Zynex Sets First Quarter 2024 Earnings Call • PR Newswire (US) • 04/18/2024 01:15:00 PM
- Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award • PR Newswire (US) • 04/02/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:15:17 PM
- Zynex Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 02/29/2024 09:01:00 PM
- Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call • PR Newswire (US) • 02/22/2024 02:15:00 PM
- Zynex Introduces New Products • PR Newswire (US) • 02/20/2024 02:15:00 PM
- Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023 • GlobeNewswire Inc. • 02/08/2024 02:00:00 PM
- Zynex Receives FDA Clearance for its Next Generation NMES Device • PR Newswire (US) • 02/06/2024 02:15:00 PM
- Zynex Recognized in Top 25 Medical Device Companies for 2024 • PR Newswire (US) • 02/02/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 10:55:32 PM
- Zynex to Participate at the Needham Annual Growth Conference • PR Newswire (US) • 01/08/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:15:06 PM
- Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024" • PR Newswire (US) • 11/15/2023 02:15:00 PM
- Zynex Submits FDA Application for its Next Generation NMES Device • PR Newswire (US) • 11/13/2023 02:15:00 PM
- Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year • PR Newswire (US) • 11/09/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 01:20:20 PM
- Zynex Announces Share Repurchase Program • PR Newswire (US) • 11/01/2023 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 09:20:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 10:50:12 AM
- Zynex Announces Review of Strategic Alternatives • PR Newswire (US) • 10/31/2023 10:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 09:01:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:05:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM